Replimune kickstarts Phase III melanoma trial studying RP1 immunotherapy
IGNYTE-3 is a Phase III trial investigating Replimune’s flagship oncolytic treatment for advanced, treatment-resistant melanoma.
IGNYTE-3 is a Phase III trial investigating Replimune’s flagship oncolytic treatment for advanced, treatment-resistant melanoma.
What's Your Reaction?
